Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. Among authors: hudis ca. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A, Currie V, Yao TJ, Hudis C, Seidman A, et al. Crown J, et al. Cancer. 1993 Feb 15;71(4):1254-7. doi: 10.1002/1097-0142(19930215)71:4<1254::aid-cncr2820710414>3.0.co;2-x. Cancer. 1993. PMID: 8435802 Clinical Trial.
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. Hudis C, et al. Eur J Cancer. 1997 Nov;33(13):2198-202. doi: 10.1016/s0959-8049(97)00254-2. Eur J Cancer. 1997. PMID: 9470806 Clinical Trial.
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L. Hudis C, et al. Cancer Invest. 1998;16(2):67-71. doi: 10.3109/07357909809039759. Cancer Invest. 1998. PMID: 9512671 Clinical Trial. No abstract available.
471 results